[Transscleral and transpupillary laser coagulation in proliferative sickle-cell retinopathy].

Ophthalmologe

Klinik für Augenheilkunde, Marienhospital Osnabrück, Johannisfreiheit 2-4, 49074 Osnabrück.

Published: February 2001

Background: Transscleral diode laser photocoagulation is a new method for treating proliferative sickle-cell retinopathy (PSR). Other treatments include transpupillary laser photocoagulation and transscleral cryocoagulation

Case Report: We report two patients with sickle-cell disease and PSR, one treated by transpupillary argon laser coagulation and the other by transscleral diode laser scatter photocoagulation.

Conclusion: Transpupillary and transscleral laser photocoagulation are effective and safe in the treatment of PSR. Transscleral photocoagulation is an alternative treatment method in eyes with PSR and cloudy optical media or with poor mydriasis in which transpupillary coagulation cannot be performed.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s003470170184DOI Listing

Publication Analysis

Top Keywords

laser photocoagulation
12
transpupillary laser
8
laser coagulation
8
proliferative sickle-cell
8
transscleral diode
8
diode laser
8
laser
6
transscleral
5
[transscleral transpupillary
4
coagulation proliferative
4

Similar Publications

Background: Non-proliferative and proliferative diabetic retinopathy are common complications of diabetes and a major cause of sight loss. Anti-vascular endothelial growth factor drugs represent a treatment option for people with diabetic retinopathy and are routinely used to treat various other eye conditions. However, anti-vascular endothelial growth factor drugs are expensive relative to current care options, and it is unclear whether this additional cost is justified when the immediate risk of vision loss is lower compared to patients with more aggressive ophthalmological conditions.

View Article and Find Full Text PDF

Purpose: We report a case of Eales disease in Inuit and reflect on advances in telemedicine and treatment of retinal disease since the first report of Eales' disease in Greenlandic Inuit was published.

Patients And Methods: A 41-year-old Inuit female complaining of blurred vision was referred to our eye department. There had been no sign of diabetic retinopathy during diabetic eye screening and the patient had been treated for tuberculosis in 2010.

View Article and Find Full Text PDF

Clinical features, diagnosis, management, and prognosis of circumscribed choroidal hemangioma.

Surv Ophthalmol

January 2025

Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China; Key Lab of Ocular Fundus Diseases, Chinese Academy of Medical Sciences, Beijing 100730, China. Electronic address:

Because of its benign nature and rarity, circumscribed choroidal hemangioma (CCH) often receives limited attention, leading to a high rate of misdiagnosis and a lack of standardized treatment protocols. We provide a thorough clarification of the demographics, clinical features, diagnosis, management, and prognosis of CCH. We conducted a systematic search of the PubMed, EMBASE, and Ovid databases up to December, 2023, to identify relevant studies.

View Article and Find Full Text PDF

Branch retinal vein occlusion (BRVO) is a common retinal vascular condition and a significant contributor to vision loss worldwide, particularly in middle-aged and elderly populations. This review synthesizes current knowledge on the epidemiology, pathogenesis, and clinical features of BRVO, alongside recent advancements in diagnostic and therapeutic strategies. BRVO is approximately four times more prevalent than central retinal vein occlusion (CRVO) and often leads to significant vision impairment.

View Article and Find Full Text PDF

Background: The principal objective of our study is to evaluate the characteristics of babies with type 1 ROP, screening practices and treatment trends in a tertiary care centre in Pakistan.

Methods: This prospective study at Mayo Hospital, Lahore (July 2022-July 2024), included 89 preterm infants with type 1 ROP, selected using non-probability sampling. Infants were categorized based on international (GA < 32weeks or BW < 1500 g) and local screening criteria (GA < 35 weeks or BW < 2000 g), and treatment outcomes were evaluated across three groups: Anti-VEGF, combination therapy (Anti-VEGF followed by laser), and laser therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!